pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Forbion secures $2.6 billion in its biggest European venture fund to date

Oct 7, 2026·read at STAT ↗DealPositive

Forbion, a leading European venture capital firm, announced it has closed a $2.6 billion fund, the largest it has raised and among the biggest recent funds in the region.

The new capital will be deployed to back biotech and life‑science companies across Europe, continuing Forbion’s strategy of supporting innovative drug development.

The raise underscores growing investor appetite for European biotech, as the sector seeks funding to advance pipelines in areas such as rare diseases and novel therapeutics.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Forbion raises $2.6 billion, its largest fundraise to date”

read at STAT ↗
573 words · retrieved 52m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECACaribou Biosciences, Inc.LEADINGUltragenyx Pharmaceutical Inc.
drugs
Obesity2
topics
Duchenne Muscular Dystrophy2Obesity2ApprovalCAR-TGLP-1 receptorRare Disease

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: KymaThera corrals $80M; RougeTx lifts off with $58MFierce Biotech
  • Sep 29STAT+: AstraZeneca invests $2 billion in Summit TherapeuticsSTAT
  • Sep 24Chutes & Ladders—Travere chief makes way for former Amicus CEOFierce Biotech
  • Sep 4This week in charts: China deals, stock flatlines and Lilly’s M&A spreeBioPharma Dive